Canaccord Genuity Assumes ChemoCentryx at Buy, Announces Price Target of $81
Benzinga Newsdesk 4 years ago
NewsPrice TargetInitiationAnalyst Ratings
Canaccord Genuity analyst Edward Nash assumes ChemoCentryx (NASDAQ:CCXI) with a Buy rating and announces Price Target of $81.
Canaccord Genuity analyst Edward Nash assumes ChemoCentryx (NASDAQ:CCXI) with a Buy rating and announces Price Target of $81.